All In Biotech

Drug Trial Radar · NCT07245368

Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending and Multiple Ascending Dose Study Investigating PRA-216 in Healthy Volunteers Followed by a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study in Participants With Mild-to-Moderate Asthma

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Nov 4, 2025

Primary completion

Oct 1, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Prana Therapies IncIndustry
Sponsor type
Industry
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 1 of this study will consist of 2 parts * Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous (IV) or subcutaneous (SC). * Part 2 will evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of PRA-216 in healthy volunteers with repeat doses of multiple ascending dose administered subcutaneously. Phase 2a of this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity of PRA-216 in participants with mild to moderate asthma. The dose of PRA-216 for this phase was determined from Phase 1.

Conditions

  • Mild to Moderate Asthma

Interventions

  • PRA-216Drug

    biologic

  • PlaceboDrug

    matching placebo for PRA-216

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) with a single dose of PRA-216 in healthy volunteers (SAD arm)Time frame: Up to Study Day 169
  2. Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) of multiple doses of PRA-216 in healthy volunteers (MAD arm)Time frame: up to Study Day 169
  3. Phase 2a: To evaluate the effect of multiple doses of PRA-216 compared to placebo on exhaled nitric oxide (FeNO) in asthma participantsTime frame: Up to Study Day 57

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Emertitus Research Sydney

    Botany, New South Wales, Australia · Recruiting

  • Emeritus Research Camberwell

    Camberwell, Victoria, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Not yet recruiting

  • Linear

    Joondalup, Western Australia, Australia · Recruiting

  • Linear

    Nedlands, Western Australia, Australia · Recruiting

  • PCRN Waikato, Nawton

    Hamilton, Auckland, New Zealand · Recruiting

  • Pacific Clinical Research Network-Auckland

    Takapuna, Auckland, New Zealand · Recruiting

  • PCRN Wellington, Ebdentown

    Upper Hutt, Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.